ETF · real data, updated daily
LABD · Direxion Daily S&P Biotech Bear 3x Shares
Over the last 11 years (2015-06 to 2026-09), $10,000 invested in LABD with dividends reinvested grew to $1, -54.21% a year, with a worst peak-to-trough fall of -99.99%. Past performance doesn't predict future results.
Growth of $10,000 · 2015-06 to 2026-09 · dividends reinvested
How LABD held up in past market crashes
LABD has been through 3 of the market crashes since 2000 in our data. Its deepest price fall was 80.5% in the 2022 bear market, when the S&P 500 fell 25.4%. Its price had not yet regained that high by the latest close (price only, not counting the dividends or interest it paid). No fund is safe from losses; past falls do not predict future ones.
| Crash | LABD deepest fall | S&P 500 (SPY) | Peak to bottom | Back to peak |
|---|---|---|---|---|
| 2018 fourth-quarter selloff | -34.2% | -20.2% | Nov 2018 to Dec 2018 | 1 months |
| 2020 COVID crash | -23.8% | -34.1% | Mar 2020 to Mar 2020 | Not yet |
| 2022 bear market | -80.5% | -25.4% | May 2022 to Aug 2022 | Not yet |
Price declines in the fund's listing currency, dividends not included, inside each crash's S&P 500 peak-to-bottom window. See how 50 popular ETFs compare in the crash study.
About LABD
Direxion Daily S&P Biotech Bear 3X Shares is a leveraged inverse exchange-traded fund designed to deliver daily investment results that are the opposite, at three times the magnitude, of the S&P Biotechnology Select Industry Index. The fund uses financial instruments such as swap agreements, futures contracts, and short positions to create its exposure to U.S. biotechnology companies. Its strategy is centered on short-term index tracking rather than long-term holding, making it a specialized tool for market participants seeking daily bearish exposure to the biotechnology sector. LABD is part of Direxion’s lineup of sector-focused leveraged ETFs and plays a distinct role in providing tactical access to biotechnology market movements without directly owning the underlying stocks.
Put LABD to the test
Every tool below opens prefilled with LABD: free, no account needed.
Backtest LABD →
Full history, any date range, benchmarks, drawdowns, rolling returns.
Would LABD survive 2008? →
What actually happened to it in the crisis: real drawdown and recovery.
Project it forward →
Monte Carlo simulation of where it could go from here.
Compare LABD vs VTI →
Head-to-head against the total US market.
Replay $100/mo into LABD →
Animated growth of steady monthly contributions.
Fundamentals →
Holdings-level financials where available.
Educational use only, not investment advice. Results are hypothetical.Read full disclaimer
This tool is for educational and informational purposes only and does not provide financial, investment, tax, legal, or accounting advice. Results are hypothetical and based on historical data and assumptions that may be inaccurate. Past performance does not guarantee future results. Consult a licensed professional before making investment decisions.